Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Sales (2016 - 2025)

Historic Return on Sales for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 84.7%.

  • Northwest Biotherapeutics' Return on Sales fell 374200.0% to 84.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 78.38%, marking a year-over-year decrease of 347300.0%. This contributed to the annual value of 53.74% for FY2024, which is 223000.0% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Return on Sales of 84.7% as of Q3 2025, which was down 374200.0% from 126.76% recorded in Q2 2025.
  • Northwest Biotherapeutics' Return on Sales' 5-year high stood at 15.9% during Q1 2023, with a 5-year trough of 126.76% in Q2 2025.
  • Its 5-year average for Return on Sales is 56.41%, with a median of 47.29% in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Return on Sales skyrocketed by 42657400bps in 2021, and later crashed by -892200bps in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Return on Sales (Quarter) stood at 57.43% in 2021, then soared by 43bps to 32.49% in 2022, then decreased by -13bps to 36.82% in 2023, then plummeted by -147bps to 90.85% in 2024, then increased by 7bps to 84.7% in 2025.
  • Its last three reported values are 84.7% in Q3 2025, 126.76% for Q2 2025, and 50.43% during Q1 2025.